• Telomir Pharmaceuticals priced a $5.6 million PIPE, issuing 4,843,300 common shares in an unregistered private placement.
• Shares sold at USD 1.16 each, a 5% discount to the applicable 10-day VWAP.
• John Paul DeJoria invested an additional USD 1 million; he previously reported about 3.55 million shares, or roughly 5% ownership.
• Proceeds earmarked mainly for Telomir-Zn clinical development, including a Phase 1/2 trial in advanced or metastatic triple-negative breast cancer.
• No investor warrants, convertible securities, or variable-price features; resale registration statement planned under a registration rights agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060800PRIMZONEFULLFEED9840199) on October 06, 2026, and is solely responsible for the information contained therein.